Nigeria’s government has pledged to cut cancer deaths by 30% by 2030. But TheDigger’s investigations reveal five critical, unresolved failures that threaten to make the promise unattainable: a system that cannot measure, cannot supply, cannot verify, and cannot afford the very essentials the pledge requires. KEHINDE ADEGOKE unearths.
Nigeria has set itself a bold target: cut cancer deaths by nearly a third within just four years. But behind the headline pledge lies a stark reality — a health system without the numbers to measure progress, without the safeguards to guarantee genuine drugs, without the machines to deliver treatment, without the political will to confront pricing, and without the money to match its ambition. What emerges is not a roadmap to victory over cancer, but a collision course between promise and crisis, where patients are already paying the price.
1. A Target With No Verified Starting Point
As TheDigger has previously reported, Nigeria’s cancer data infrastructure is officially classified by the International Agency for Research on Cancer at Category IV — hospital- or pathology-based registration only, with rates that often cannot be calculated at all. Just four of the country’s registries feed into global data, covering under 4 per cent of the population. NICRAT only validated the country’s first-ever national registry standard operating procedure on June 29, 2026 — three weeks before the 30-by-2030 target was announced. A reduction target needs a number to reduce from. Nigeria does not yet have one it can defend.
2. A Drug Supply Nobody Can Certify as Genuine
This is where the picture turns darker. In an earlier investigation, this newsroom exposed a 60-percentage-point gulf between Nigeria’s two most relevant regulators: NAFDAC’s 11 per cent estimate of counterfeit medicine prevalence versus the National Primary Healthcare Development Agency’s 2022 finding of 71 per cent — a near-fifteen-fold miss against NAFDAC’s own 5-per cent-by-2025 target, now quietly expired without a published verdict. NAFDAC’s last independent national survey dates to 2005. The agency publicly called for a new one in 2019. Seven years later, it still hasn’t happened.
That data vacuum is not theoretical for cancer patients — it is already killing them. TheDigger documented counterfeit Phesgo, a breast cancer drug, reaching Lagos University Teaching Hospital, Nigeria’s premier referral centre, as part of a synchronised international network also hitting Turkey and the Philippines. Separately, NAFDAC confirmed that fake Avastin and Tecentriq are circulating in the Nigerian supply chain, sold for between ₦180,000 and ₦350,000 — below the genuine price, which is itself the lure. A national plan promising better cancer outcomes by 2030 says nothing about closing this gap, even though this newsroom’s own reporting shows the counterfeit network is not a future risk but a present one, operating inside the country’s flagship teaching hospital today.
3. Machines the Plan Doesn’t Mention
Nigeria needs a minimum of 280 radiotherapy machines for its population; it has eight government-funded ones, and three-quarters of those weren’t even treating patients in the most recent peer-reviewed survey due to non-functional equipment. Independent expert estimates in 2026 put the true national functional count — public and private combined — at roughly ten. Brachytherapy, essential for cervical cancer, exists at fewer than 10 centres nationwide against an estimated need of 200. None of this capacity gap is quantified in the government’s public statements about the 2026–2030 Plan.
4. The Price Nigeria Never Asks About
TheDigger’s May 2026 investigation into Keytruda — the world’s best-selling cancer drug, priced above $200,000 per patient per year in some markets — found that while lawmakers in the Netherlands, Belgium, Austria, Finland and the United States have opened formal probes into its pricing, not one Nigerian senator or House member has raised the issue on the floor of the National Assembly, despite Nigeria recording an estimated 78,000 cancer deaths annually. Compounding that silence, TheDigger’s investigation into Merck’s fixed-dose strategy found the company dispenses the same 200mg dose regardless of patient weight — a practice oncologists call commercially, not clinically, motivated, and one the WHO estimates costs global health systems $5 billion in avoidable spending through 2040. The Netherlands, Canada and Israel have switched to weight-based dosing to cut costs. Nigeria has not joined that conversation, in Parliament or in policy.
5. A Fund That Doesn’t Match the Ambition
The Plan’s only disclosed new financing mechanism is a ₦50 million Social Determinants of Health Fund that covers patient transport costs — chaired by Mayo Clinic’s global oncology director, Folakemi Odedina, whose Technical Working Group members reportedly made personal donations to it. The Minister of State for Health has himself acknowledged that funding for cancer care “remains inadequate.” No published, itemised budget for the full 2026–2030 Plan has been made public.
The Pattern
Individually, each of these five gaps has already been documented by this newsroom. Together, they describe a country announcing a precise, quantified national health outcome — 30 per cent, by 2030 — without a verified baseline to measure it against, a drug supply it cannot certify as safe, treatment machines at roughly 3 percent of required capacity, a pricing crisis its legislature has never discussed, and a financing plan an order of magnitude smaller than the problem it addresses.
TheDiggerNews.com is formally renewing its outstanding questions to the Federal Ministry of Health, NAFDAC, and NICRAT: What is the full costed budget for the National Cancer Control Plan 2026–2030? What is the current, verified count of functional government radiotherapy machines? And has any agency reconciled the 60-point gap between NAFDAC’s and the NPHCDA’s counterfeit medicine figures — a gap directly relevant to whether cancer patients on treatment today are receiving genuine drugs? Responses will be published in full upon receipt.
Kehinde Adegoke is an award-winning investigative journalist with more than 15 years of distinguished experience uncovering stories that shape public discourse. With three industry nominations across diverse beats, he has earned recognition for fearless reporting, incisive analysis, and a commitment to accountability. As Managing Editor and CEO of TheDiggerNews.com, Adegoke leads a pioneering newsroom dedicated to exposing hidden truths, amplifying marginalised voices, and setting new standards in investigative journalism.
TheDiggerNews.com | www.thediggernews.com | 08039135472 | Ibadan, Nigeria
